1. Home
  2. Browse
  3. HRA000559
HRA000559
   HRA000559.xlsx
Title:
T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after Daratumumab-based therapy
Release date:
2021-01-13
Description:
immunoglobulin light chain amyloidosis (AL) is a systemic disease characterized by the presence of modest and indolent B cell clones with the production and deposition of abnormally folded monoclonal light chains into a range of tissues. Monoclonal antibody Daratumumab (anti-CD38) has shown promising efficacy for the treatment of AL. T cell changes within the tumor microenvironment are closely associated with the progression and/or prognosis of a variety of tumors, whereas the study of T cell alteration in AL is scarce. By sequencing at single cell level of CD3+ T cells purified from bone marrow (BM) and blood of AL patients before and after Daratumumab (DARA)-based therapy with cyclophosphamide, bortezomib, and dexamethasone, we analyzed the transcriptomic features of T cells and found an expansion, activation, and type I cytokine upregulation in BM and circulating T cells after the treatment.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA004206
Study type:
Disease Study
Disease name:
AMYLOIDOSIS
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC000371
DAC name:
geqing
Contact person:
ge qing
Email:
geqinggq717@163.com
Description:
xxxx
Individuals & samples
Files
Request Data
Submitter:   Ge Qing / qingge@bjmu.edu.cn
Organization:   http://www.bjmu.edu.cn
Submission date:   2021-01-07
Requests:   -